TABLE 3

Summary of statistical analysis of secondary endpoint data (ITT population)

Placebo (N = 42)Nemiralisib 1000 µg (N = 42)
nPosterior Median (S.D.)95% CrInPosterior Median (S.D.)95% CrI
Trough FEV1 (L) fold change from baselineDay 7391.24 (1.99)−2.63, 5.1240−0.77 (1.97)−4.70, 3.04
Day 14380.50 (1.91)−3.34, 4.13410.54 (1.89)−3.26, 4.10
Day 28370.97 (1.72)−2.52, 4.30390.31 (1.72)−3.23, 3.50
Weighted mean (0–4 h) FEV1 (L)Day 28382.67 (0.06)2.56, 2.78402.72 (0.06)2.61, 2.84
Trough FVC (L) change from baselineDay 7390.04 (0.06)−0.08, 0.15400.02 (0.06)−0.10, 0.13
Day 1438−0.00 (0.06)−0.11, 0.11410.04 (0.06)−0.07, 0.15
Day 28370.02 (0.05)−0.09, 0.12390.05 (0.05)−0.05, 0.16
Trough FEV1/FVC (%) change from baselineDay 739−0.96 (0.72)−2.34, 0.5040−0.86 (0.71)−2.29, 0.52
Day 1438−0.46 (0.75)−1.94, 0.9941−0.44 (0.73)−1.90, 0.99
Day 2837−0.69 (0.69)−2.05, 0.6439−0.79 (0.68)−2.16, 0.52
ACT score change from baselineDay 28381.4 (0.45)0.5, 2.2401.9 (0.43)1.0, 2.7
Trough FeNO (ppb) fold change from baselineDay 7381.03 (0.05)0.93, 1.13340.91 (0.05)0.82, 1.01
Day 14340.99 (0.06)0.89, 1.11350.95 (0.06)0.85, 1.05
Day 28341.03 (0.07)0.91, 1.17341.03 (0.06)0.91, 1.17
  • ppb, parts per billion.